Roy Fleischmann
Dallas, TXNPI 1467451146
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $649,481 of the $1,046,887 with a category attached, or 62.0%. 30 manufacturers reported payments, led by AbbVie at 44.4% of the total. Reporting peaked in 2019 at $299,383 and has fallen 72.8% since, to $81,560 in 2025.
Across 982 payments — averaging $1066.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$465K
- Pfizer$228K
- GSK$67K
- Eli Lilly$66K
- Novartis$42K
- E.r. Squibb & Sons, L.L.C.$42K
- plus $137K from 24 others
Across 674 payments — averaging $4178.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$611K
- UCB SA$517K
- Eli Lilly$279K
- Amgen$260K
- E.r. Squibb & Sons, L.L.C.$204K
- Regeneron$198K
- plus $746K from 14 others
What the payments were for
- Consulting fees$649,48162%
- Speaking & faculty fees$271,72326%
- Grants$25,0002%
- Travel & lodging$89,4419%
- Food & beverage$11,0781%
- Education$1640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 282 | $464,569 |
| Pfizer | 148 | $228,056 |
| GSK | 40 | $67,063 |
| Eli Lilly | 78 | $66,441 |
| Novartis | 93 | $41,829 |
| E.r. Squibb & Sons, L.L.C. | 60 | $41,573 |
| Janssen Scientific Affairs, LLC | 140 | $31,828 |
| Lilly USA, LLC | 16 | $23,333 |
| Gilead | 14 | $14,306 |
| Boehringer Ingelheim | 13 | $14,190 |
| Whitehall International Inc | 1 | $8,500 |
| Merck | 10 | $8,332 |
| UCB SA | 14 | $6,351 |
| Pfizer Chile S.A. | 1 | $6,300 |
| Amgen | 8 | $5,702 |
| Sanofi | 20 | $4,136 |
| Eisai Inc. | 1 | $2,000 |
| Mylan Inc. | 1 | $1,953 |
| Genentech USA, Inc. | 9 | $1,705 |
| Celltrion, Inc. | 1 | $1,650 |
| Almirall LLC | 1 | $1,600 |
| Genentech, Inc. | 21 | $1,285 |
| Samsung Bioepis Co., Ltd. | 1 | $800 |
| Roche Products Limited | 1 | $800 |
| Galderma Laboratories, L.p. | 1 | $800 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $600 |
| Celltrion Healthcare Co., Ltd | 1 | $600 |
| Assertio Therapeutics, Inc. | 2 | $475 |
| AstraZeneca | 1 | $62 |
| Aurinia Pharma U.S., Inc. | 2 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.